Clinical Trials Browser

Phase 1/2 × Neoplasm, Residual × avelumab × Clear all

NCT03699384 2019-02-20

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual